JP6865038B2 - Ｎａｆｌｄおよびｎａｓｈの治療 - Google Patents

Ｎａｆｌｄおよびｎａｓｈの治療 Download PDF

Info

Publication number
JP6865038B2
JP6865038B2 JP2016561799A JP2016561799A JP6865038B2 JP 6865038 B2 JP6865038 B2 JP 6865038B2 JP 2016561799 A JP2016561799 A JP 2016561799A JP 2016561799 A JP2016561799 A JP 2016561799A JP 6865038 B2 JP6865038 B2 JP 6865038B2
Authority
JP
Japan
Prior art keywords
nash
nafld
mbx
liver
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016561799A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017513836A (ja
JP2017513836A5 (enExample
Inventor
ブライアン・ロバーツ
シュエヤン・ワン
ヨンジュン・チェ
デイビッド・カーフ
ロバート・マーティン
チャールズ・エイ・マックウェーター
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CymaBay Therapeutics Inc
Original Assignee
CymaBay Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53373532&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6865038(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by CymaBay Therapeutics Inc filed Critical CymaBay Therapeutics Inc
Publication of JP2017513836A publication Critical patent/JP2017513836A/ja
Publication of JP2017513836A5 publication Critical patent/JP2017513836A5/ja
Application granted granted Critical
Publication of JP6865038B2 publication Critical patent/JP6865038B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2016561799A 2014-04-11 2015-04-10 Ｎａｆｌｄおよびｎａｓｈの治療 Active JP6865038B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461978335P 2014-04-11 2014-04-11
US61/978,335 2014-04-11
PCT/US2015/025416 WO2015157697A1 (en) 2014-04-11 2015-04-10 Treatment of nafld and nash

Publications (3)

Publication Number Publication Date
JP2017513836A JP2017513836A (ja) 2017-06-01
JP2017513836A5 JP2017513836A5 (enExample) 2018-05-24
JP6865038B2 true JP6865038B2 (ja) 2021-04-28

Family

ID=53373532

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016561799A Active JP6865038B2 (ja) 2014-04-11 2015-04-10 Ｎａｆｌｄおよびｎａｓｈの治療

Country Status (27)

Country Link
US (7) US9381181B2 (enExample)
EP (1) EP3129018B1 (enExample)
JP (1) JP6865038B2 (enExample)
KR (1) KR102374499B1 (enExample)
CN (1) CN106163508A (enExample)
AU (1) AU2015243239B2 (enExample)
BR (1) BR112016023269A8 (enExample)
CA (1) CA2944139C (enExample)
CL (1) CL2016002517A1 (enExample)
CY (1) CY1122602T1 (enExample)
DK (1) DK3129018T3 (enExample)
EA (1) EA036704B1 (enExample)
ES (1) ES2764467T3 (enExample)
HR (1) HRP20192299T1 (enExample)
IL (1) IL248193B (enExample)
LT (1) LT3129018T (enExample)
MX (1) MX369921B (enExample)
NZ (1) NZ724740A (enExample)
PH (1) PH12016501978B1 (enExample)
PL (1) PL3129018T3 (enExample)
PT (1) PT3129018T (enExample)
RS (1) RS59637B1 (enExample)
SG (1) SG11201608077PA (enExample)
SI (1) SI3129018T1 (enExample)
SM (1) SMT202000019T1 (enExample)
UA (1) UA121208C2 (enExample)
WO (1) WO2015157697A1 (enExample)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3187182B1 (en) 2008-09-02 2021-03-03 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
BRPI0920170A2 (pt) 2008-10-17 2016-06-21 Metabolex Inc métodos para diminuir a quantidade de partículas ldl pequenas e densas e de níveis de triglicerídeos e ldl no sangue em um humano, e para identificar um indivíduo candidato para tratamento com um composto ou um sal, prodroga ou isômero do mesmo, composto ou um sal, prodroga ou isômero do mesmo, e método.
EP4008327A1 (en) 2009-04-29 2022-06-08 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
KR101343249B1 (ko) 2009-04-29 2013-12-19 아마린 파마, 인크. 안정한 제약 조성물 및 그의 사용 방법
EP3318255B1 (en) 2009-06-15 2021-03-10 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating stroke in a subject on concomitant statin therapy
KR101798670B1 (ko) 2009-09-23 2017-11-16 아마린 코포레이션 피엘씨 오메가-3 지방산 및 스타틴의 히드록시-유도체를 포함하는 제약 조성물 및 그의 사용 방법
WO2011140441A2 (en) 2010-05-06 2011-11-10 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
NZ757815A (en) 2010-11-29 2020-05-29 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
WO2013070735A1 (en) 2011-11-07 2013-05-16 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
JP6307442B2 (ja) 2012-01-06 2018-04-04 アマリン ファーマシューティカルス アイルランド リミテッド 対象の高感度（ｈｓ−ｃｒｐ）のレベルを低下させる組成物および方法
FI3815684T3 (fi) 2012-06-29 2024-09-30 Amarin Pharmaceuticals Ie Ltd Menetelmiä sydän- ja verisuoniperäisen tapahtuman riskin alentamiseksi statiinihoitoa saavassa kohteessa
US20150265566A1 (en) 2012-11-06 2015-09-24 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en) * 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
LT3119384T (lt) 2014-03-20 2018-11-26 Cymabay Therapeutics, Inc. Intrahepatinių cholestazinių ligų gydymas
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
CN106163508A (zh) 2014-04-11 2016-11-23 西玛贝医药公司 Nafld和nash的治疗
EP3712254A1 (en) 2014-05-28 2020-09-23 Children's Hospital Medical Center Methods and systems for converting precursor cells into gastric tissues through directed differentiation
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
WO2016061464A1 (en) 2014-10-17 2016-04-21 Children's Hospital Center, D/B/A Cincinnati Children's Hospital Medical Center In vivo model of human small intetine using pluripotent stem cells and methods of making and using same
WO2016154258A1 (en) * 2015-03-26 2016-09-29 T3D Therapeutics, Inc. Methods of treating liver disease using indane acetic acid derivatives
KR20240033300A (ko) 2015-04-28 2024-03-12 바스프 에이에스 비알코올성 지방간염의 예방 및/또는 치료를 위한 구조적으로 강화된 함황 지방산의 용도
US10940125B2 (en) 2015-09-18 2021-03-09 Duke University Methods and compositions for the treatment of steatosis-associated disorders
WO2017139708A1 (en) 2016-02-10 2017-08-17 Synlogic, Inc. Bacteria engineered to treat nonalcoholic steatohepatitis (nash)
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US12053445B2 (en) 2016-03-31 2024-08-06 Genfit Methods of treatment of cholestatic diseases
CA3016641A1 (en) 2016-05-05 2017-11-09 Children's Hospital Medical Center Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same
GB201614455D0 (en) 2016-08-24 2016-10-05 Univ Oxford Innovation Ltd Biomarkers
KR102546194B1 (ko) * 2016-11-04 2023-06-21 칠드런즈 호스피탈 메디칼 센터 간 유사 장기 조성물 및 이를 제조 및 사용하는 방법
US10493363B2 (en) * 2016-11-09 2019-12-03 Activision Publishing, Inc. Reality-based video game elements
KR102807995B1 (ko) 2016-12-05 2025-05-16 칠드런즈 호스피탈 메디칼 센터 결장 유사장기 및 이를 제조 및 사용하는 방법
JP7248586B2 (ja) 2017-04-14 2023-03-29 チルドレンズ ホスピタル メディカル センター 複数ドナー幹細胞組成物およびそれを作製する方法
TWI762634B (zh) 2017-05-05 2022-05-01 大陸商上海赫普化醫藥技術有限公司 胺基-芳基-苯甲醯胺化合物及其使用方法
TW201900160A (zh) 2017-05-19 2019-01-01 愛爾蘭商艾瑪琳製藥愛爾蘭有限公司 用於降低腎功能下降之個體中的三酸甘油酯之組合物及方法
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
WO2019053582A1 (en) 2017-09-13 2019-03-21 Novartis Ag COMBINATIONS HAVING FXR AGONISTS
WO2019074793A1 (en) 2017-10-10 2019-04-18 Children's Hospital Medical Center OESOPHAGIAN TISSUE COMPOSITIONS AND / OR ORGANOIDS AND METHODS OF MAKING SAME
WO2019083070A1 (ko) * 2017-10-27 2019-05-02 주식회사 삼양사 비알코올성 지방간 질환의 예방 또는 개선용 조성물
EP3720431B1 (en) 2017-12-06 2024-10-30 Basf As Fatty acid derivatives for treating non-alcoholic steatohepatitis
WO2019126626A1 (en) 2017-12-21 2019-06-27 Children's Hospital Medical Center Digitalized human organoids and methods of using same
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
CA3106634A1 (en) 2018-07-26 2020-01-30 Children's Hospital Medical Center Hepato-biliary-pancreatic tissues and methods of making same
US12428622B2 (en) 2018-09-12 2025-09-30 Children's Hospital Medical Center Organoid compositions for the production of hematopoietic stem cells and derivatives thereof
KR20210110890A (ko) 2018-09-24 2021-09-09 애머린 파마슈티칼스 아일랜드 리미티드 대상체에서 심혈관 사건의 위험도를 감소시키는 방법
EA202191379A1 (ru) 2018-11-16 2021-08-06 Саймабэй Терапьютикс, Инк. Комбинированное лечение nafld и nash
MX2021005725A (es) 2018-11-16 2021-07-21 Cymabay Therapeutics Inc Tratamiento de la obesidad y sus complicaciones.
CN111320609A (zh) 2018-12-13 2020-06-23 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
US12398127B2 (en) 2019-09-12 2025-08-26 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
US12427134B2 (en) 2019-11-12 2025-09-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter
US20210145774A1 (en) 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Treatment of alcoholic liver disease
US20210145775A1 (en) 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Treatment of intestinal barrier dysfunction and associated diseases
EP4149452A4 (en) * 2020-05-13 2024-05-01 Terns Pharmaceuticals, Inc. COMBINATION TREATMENT OF LIVER DISEASES
AU2022263358A1 (en) 2021-04-21 2023-11-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure
WO2022238445A1 (en) * 2021-05-11 2022-11-17 Genfit Ppar-agonists for use in the treatment of liver failure

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7101993B1 (en) 1990-01-11 2006-09-05 Isis Pharmaceuticals, Inc. Oligonucleotides containing 2′-O-modified purines
US7015315B1 (en) 1991-12-24 2006-03-21 Isis Pharmaceuticals, Inc. Gapped oligonucleotides
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US6166197A (en) 1995-03-06 2000-12-26 Isis Pharmaceuticals, Inc. Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
EP0813539B1 (en) 1995-03-06 2006-05-24 Isis Pharmaceuticals, Inc. Improved process for the synthesis of 2'-o-substituted pyrimidines and oligomeric compounds therefrom
WO1997030067A1 (en) 1996-02-14 1997-08-21 Isis Pharmaceuticals, Inc. Sugar-modified gapped oligonucleotides
US5883109A (en) 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
US6066653A (en) 1997-01-17 2000-05-23 Bristol-Myers Squibb Co. Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US7511131B2 (en) 2002-11-13 2009-03-31 Genzyme Corporation Antisense modulation of apolipoprotein B expression
SG145752A1 (en) 2003-09-19 2008-09-29 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
SI1725234T1 (sl) 2004-03-05 2013-04-30 The Trustees Of The University Of Pennsylvania Postopki zdravljenja nepravilnosti ali bolezni povezanih s hiperlipidemijo in hiperholesterolemijo z minimiziranjem stranskih uäśinkov
JO3006B1 (ar) * 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
US20080176861A1 (en) 2007-01-23 2008-07-24 Kalypsys, Inc. Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis
BRPI0920170A2 (pt) 2008-10-17 2016-06-21 Metabolex Inc métodos para diminuir a quantidade de partículas ldl pequenas e densas e de níveis de triglicerídeos e ldl no sangue em um humano, e para identificar um indivíduo candidato para tratamento com um composto ou um sal, prodroga ou isômero do mesmo, composto ou um sal, prodroga ou isômero do mesmo, e método.
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
AU2014353246A1 (en) 2013-11-20 2016-06-16 Cymabay Therapeutics, Inc. Treatment of homozygous familial hypercholesterolemia
LT3119384T (lt) 2014-03-20 2018-11-26 Cymabay Therapeutics, Inc. Intrahepatinių cholestazinių ligų gydymas
CN106163508A (zh) 2014-04-11 2016-11-23 西玛贝医药公司 Nafld和nash的治疗
HK1231380A1 (zh) 2014-06-26 2017-12-22 Cymabay Therapeutics, Inc. 严重高甘油三酯血症的治疗

Also Published As

Publication number Publication date
JP2017513836A (ja) 2017-06-01
LT3129018T (lt) 2020-01-10
EA036704B1 (ru) 2020-12-10
MX2016013375A (es) 2017-02-15
SI3129018T1 (sl) 2020-02-28
US20180008566A1 (en) 2018-01-11
CL2016002517A1 (es) 2017-05-05
HRP20192299T1 (hr) 2020-03-06
EP3129018B1 (en) 2019-10-23
US11179359B2 (en) 2021-11-23
EA201692050A1 (ru) 2017-01-30
DK3129018T3 (da) 2020-01-20
SG11201608077PA (en) 2016-10-28
AU2015243239A1 (en) 2016-10-20
PL3129018T3 (pl) 2020-05-18
US9381181B2 (en) 2016-07-05
KR20160136451A (ko) 2016-11-29
US10722483B2 (en) 2020-07-28
CA2944139A1 (en) 2015-10-15
US10342770B2 (en) 2019-07-09
BR112016023269A8 (pt) 2021-06-29
US10188620B2 (en) 2019-01-29
AU2015243239B2 (en) 2019-11-14
MX369921B (es) 2019-11-26
US20160324812A1 (en) 2016-11-10
US20190142776A1 (en) 2019-05-16
SMT202000019T1 (it) 2020-03-13
WO2015157697A1 (en) 2015-10-15
UA121208C2 (uk) 2020-04-27
PT3129018T (pt) 2020-01-15
NZ724740A (en) 2019-11-29
BR112016023269A2 (pt) 2017-08-15
PH12016501978A1 (en) 2016-12-19
CA2944139C (en) 2020-11-03
CY1122602T1 (el) 2021-03-12
US20180228752A1 (en) 2018-08-16
US20210038546A1 (en) 2021-02-11
US9962346B2 (en) 2018-05-08
RS59637B1 (sr) 2020-01-31
PH12016501978B1 (en) 2023-07-12
EP3129018A1 (en) 2017-02-15
IL248193B (en) 2019-03-31
US20150290154A1 (en) 2015-10-15
ES2764467T3 (es) 2020-06-03
CN106163508A (zh) 2016-11-23
US20200009092A1 (en) 2020-01-09
KR102374499B1 (ko) 2022-03-14
US9616039B2 (en) 2017-04-11

Similar Documents

Publication Publication Date Title
JP6865038B2 (ja) Ｎａｆｌｄおよびｎａｓｈの治療
JP6568577B2 (ja) 肝内胆汁うっ滞症の治療
WO2020102337A1 (en) Combination treatment of nafld and nash
WO2020102351A1 (en) Treatment of obesity and its complications
US10478411B2 (en) Treatment of intrahepatic cholestatic diseases
HK1228275A1 (en) Treatment of nafld and nash
HK1228275B (en) Treatment of nafld and nash

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180403

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180403

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190108

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190402

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190702

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20191119

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20200318

C116 Written invitation by the chief administrative judge to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C116

Effective date: 20200331

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20200331

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20201104

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20210209

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20210330

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20210330

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210405

R150 Certificate of patent or registration of utility model

Ref document number: 6865038

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250